Surufatinib
- Generic Name
- Surufatinib
- Drug Type
- Small Molecule
- Chemical Formula
- C24H28N6O3S
- CAS Number
- 1308672-74-3
- Unique Ingredient Identifier
- B2K5L1L8S9
- Background
Surufatinib is under investigation in clinical trial NCT02588170 (Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors).
- Indication
单药用于治疗无法手术切除的局部晚期或转移性、进展期非功能性、分化良好（G1、G2）的胰腺和非胰腺来源的神经内分泌瘤（pNETs）。
The Combination of Radiotherapy，Surufatinib and Sintilimab in High-Risk Localized Soft Tissue Sarcoma
- Conditions
- High-Risk Localized Soft Tissue Sarcoma
- Interventions
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 52
- Registration Number
- NCT05839275
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic Cancer
- Conditions
- Unresectable Locally Advanced or Metastatic Pancreatic Cancer
- Interventions
- First Posted Date
- 2023-04-27
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 41
- Registration Number
- NCT05832892
- Locations
- 🇨🇳
Zhongshan Hospital, Shanghai, Shanghai, China
Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer
- Conditions
- Metastatic Triple-negative Breast Cancer
- Interventions
- First Posted Date
- 2023-02-28
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Huihua Xiong
- Target Recruit Count
- 45
- Registration Number
- NCT05746728
- Locations
- 🇨🇳
Tongji Hospital Affiliated of Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China
A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma.
- Conditions
- Neuroendocrine Carcinoma
- Interventions
- First Posted Date
- 2023-02-28
- Last Posted Date
- 2023-02-28
- Lead Sponsor
- Wuhan Union Hospital, China
- Target Recruit Count
- 60
- Registration Number
- NCT05747729
- Locations
- 🇨🇳
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Surufatinib and Envafolimab as Second or More-line Therapy in Advanced Soft Tissue Sarcoma Patients
- Conditions
- Efficacy and Safety of Surufatinib Combined With Envafolimab as Second or More-line Therapy in Advanced Soft Tissue Sarcoma Patients
- Interventions
- First Posted Date
- 2023-02-10
- Last Posted Date
- 2023-02-10
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 45
- Registration Number
- NCT05722977
Surufatinib in Combination of Durvalumab and EP/EC in the Firstly-line Treatment of ES-SCLC
- Conditions
- Extensive-stage Small-cell Lung Cancer
- Interventions
- First Posted Date
- 2022-12-30
- Last Posted Date
- 2022-12-30
- Lead Sponsor
- Beijing Chest Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05668767
Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer
- First Posted Date
- 2022-12-15
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Bai-Rong Xia
- Target Recruit Count
- 37
- Registration Number
- NCT05652283
- Locations
- 🇨🇳
Anhui Cancer Hospital, Hefei, Anhui, China
Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard Chemotherapy
- Conditions
- Neuroendocrine Tumor Grade 3Neuroendocrine CarcinomaPancreatic Carcinoma
- Interventions
- First Posted Date
- 2022-11-25
- Last Posted Date
- 2022-11-25
- Target Recruit Count
- 60
- Registration Number
- NCT05627427
- Locations
- 🇨🇳
Rui Liu, Tianjin, Tianjin, China
Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer
- Conditions
- AngiogenesisChemotherapy EffectSmall Cell Lung Cancer
- Interventions
- First Posted Date
- 2022-10-27
- Last Posted Date
- 2022-11-29
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT05595889
A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma
- Conditions
- Osteosarcoma
- Interventions
- First Posted Date
- 2022-10-21
- Last Posted Date
- 2022-10-21
- Lead Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University
- Target Recruit Count
- 148
- Registration Number
- NCT05590572
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
🇨🇳Qilu Hospital of Shandong University, Jinan, Shandong, China
🇨🇳Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.